Ectopic G-CSF expression in human melanoma lines marks a trans-dominant pathway of tumor progression.
Using a human melanoma/Scid xenograft model with the C8161, M24-met, LD-1 and other human melanoma lines to investigate spontaneous metastasis, we made the observation of marked splenomegaly (up to five times normal weight and size) in only those xenografts exhibiting high degrees of spontaneous metastasis. Evaluation of this revealed the cause to be massive myelopoiesis due to ectopic granulocyte/ colony-stimulating factor (G-CSF) production by the melanoma cells. Because of these observations linking G-CSF expression with metastasis of human melanoma, we decided to investigate the mechanism of this ectopic production. No gross amplification or rearrangement of the G-CSF gene could be detected as the basis for the increased transcriptional activity in any of these lines. Human-human somatic cell hybridization studies carried out between the metastatic C8161 and several different nonmetastatic non-G-CSF-expressing lines revealed, in addition to metastatic dominance, 3- to 10-fold enhancement of G-CSF transcription and expression in the fusions compared with C8161 itself. The suggestion of a trans-dominant mechanism was further supported by transfection studies with a human G-CSF promoter-CAT-reporter construct, which revealed 3- to 5-fold increased reporter activity in only those melanoma lines and hybrids expressing G-CSF. Furthermore, no obvious autocrine or paracrine effects of this ectopic G-CSF expression on the melanoma lines' growth or metastasis were apparent, as all of the G-CSF-expressing lines lacked the G-CSF receptor and injections of purified recombinant G-CSF exerted no stimulatory effects on their tumorigenicity, latency, growth, or metastasis in Scid mice. Thus, we advance the hypothesis that G-CSF expression is serving as a marker of a more generalized trans-dominant pathway linked to tumor progression and metastasis. This hypothesis has direct relevance to many human cancers where ectopic hormone or growth factor production occurs with no obvious autocrine or paracrine benefit to the tumor.
Safarians
S
S
Department of Pathology, University of California, Los Angeles, School of Medicine 90024, USA.
Rivera
S P
SP
Sternlicht
M D
MD
Naeim
F
F
Barsky
S H
SH
D000818:Animals; D001483:Base Sequence; D002999:Clone Cells; D018450:Disease Progression; D005260:Female; D017930:Genes, Reporter; D016179:Granulocyte Colony-Stimulating Factor / Q000235:genetics*; D006801:Humans; D006822:Hybrid Cells; D007150:Immunohistochemistry; D008545:Melanoma / Q000235:genetics / Q000378:metabolism* / Q000556:secondary*; D051379:Mice; D016513:Mice, SCID; D009368:Neoplasm Transplantation; D012878:Skin Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D013154:Spleen / Q000473:pathology; D013163:Splenomegaly; D015533:Transcriptional Activation; D014407:Tumor Cells, Cultured
D016179:Granulocyte Colony-Stimulating Factor